Use of GM‐CSF in children after high‐dose chemotherapy
作者:
Wayne L. Furman,
Diane Fairclough,
Alvida M. Cain,
Bettye A. Arnold,
Charles B. Pratt,
William H. Meyer,
William M. Crist,
期刊:
Medical and Pediatric Oncology
(WILEY Available online 1992)
卷期:
Volume 20,
issue S1
页码: 26-30
ISSN:0098-1532
年代: 1992
DOI:10.1002/mpo.2950200707
出版商: Wiley Subscription Services, Inc., A Wiley Company
关键词: GM‐CSF;children;clinical trial;chemotherapy
数据来源: WILEY
摘要:
AbstractThe toxicity and efficacy of recombinant human granulocyte‐macrophage colony‐stimulating factor (rhuGM‐CSF) is established in adults [1–4], but limited information is available on its use in children [5, 6]. The profound myelotoxicity induced by cisplatin (40 mg/m2daily × 5) and etoposide (150 mg/m2daily × 3) provides a model to test the clinical value of recombinant human granulocyte‐macrophage colony‐stimulating factor in pediatric cancer patients; myelosuppression occurred (absolute neutrophil count [ANC]<500/μL) during 99 of 118 (84%) courses given to 44 children with refractory solid tumors. Fifty‐nine courses (50%) resulted in hospitalizations for fever. Subsequently, rhuGM‐CSF was added to this treatment regimen to: (i) determine the dose‐limiting toxicity of this agent in children; and (ii) to determine whether it can decrease the duration and severity of neutropenia and attendant complications. Here we summarize and update our experience with this glycoprotein in children with relapsed solid tumors. ©
点击下载:
PDF
(397KB)
返 回